BACKGROUND: AZD4877 is a potent inhibitor of the mitotic spindle kinesin, Eg5. Early-phase clinical studies in a broad range of cancers showed that AZD4877 is well tolerated. This Phase II study evaluated the efficacy, safety and pharmacokinetics (Cmax) of AZD4877 in patients with previously treated advanced urothelial cancer (ClinicalTrials.gov identifier NCT00661609). PATIENTS AND METHODS: AZD4877 25 mg was administered once-weekly for 3 weeks of each 4-week cycle until disease progression, death, unacceptable toxicity or withdrawal. The primary objective was to determine the objective response rate (RECIST). Recruitment was to be halted if ≤ 2 of the first 20 evaluable patients achieved an objective tumor response. Cmax was assessed on days 1 and 8 of cycle 1. RESULTS: None of the first 20 patients evaluable for efficacy achieved an objective response; enrollment was therefore halted. During this initial analysis, a further 21 patients were recruited. Overall, 39 patients were evaluable for efficacy, including one with confirmed partial response (PR) and seven patients with stable disease for ≥ 8 weeks (including one unconfirmed PR). The most commonly reported treatment-related adverse events (TRAEs) were neutropenia (22 patients), fatigue (12), leukopenia (7) and constipation (6); the most commonly reported grade ≥ 3 TRAE was neutropenia (21). Four patients had serious TRAEs. On days 1 and 8, the geometric mean Cmax of AZD4877 was 138 ng/ml (CV = 75 %) and 144 ng/ml (CV = 109 %), respectively. CONCLUSIONS: AZD4877 was generally tolerable in patients with advanced urothelial cancer. Given the limited clinical efficacy, further development of AZD4877 in urothelial cancer is not planned.
BACKGROUND:AZD4877 is a potent inhibitor of the mitotic spindle kinesin, Eg5. Early-phase clinical studies in a broad range of cancers showed that AZD4877 is well tolerated. This Phase II study evaluated the efficacy, safety and pharmacokinetics (Cmax) of AZD4877 in patients with previously treated advanced urothelial cancer (ClinicalTrials.gov identifier NCT00661609). PATIENTS AND METHODS: AZD4877 25 mg was administered once-weekly for 3 weeks of each 4-week cycle until disease progression, death, unacceptable toxicity or withdrawal. The primary objective was to determine the objective response rate (RECIST). Recruitment was to be halted if ≤ 2 of the first 20 evaluable patients achieved an objective tumor response. Cmax was assessed on days 1 and 8 of cycle 1. RESULTS: None of the first 20 patients evaluable for efficacy achieved an objective response; enrollment was therefore halted. During this initial analysis, a further 21 patients were recruited. Overall, 39 patients were evaluable for efficacy, including one with confirmed partial response (PR) and seven patients with stable disease for ≥ 8 weeks (including one unconfirmed PR). The most commonly reported treatment-related adverse events (TRAEs) were neutropenia (22 patients), fatigue (12), leukopenia (7) and constipation (6); the most commonly reported grade ≥ 3 TRAE was neutropenia (21). Four patients had serious TRAEs. On days 1 and 8, the geometric mean Cmax of AZD4877 was 138 ng/ml (CV = 75 %) and 144 ng/ml (CV = 109 %), respectively. CONCLUSIONS:AZD4877 was generally tolerable in patients with advanced urothelial cancer. Given the limited clinical efficacy, further development of AZD4877 in urothelial cancer is not planned.
Authors: Christopher W Lee; Karl Bélanger; Sanjay C Rao; Teresa M Petrella; Richard G Tozer; Lori Wood; Kerry J Savage; Elizabeth A Eisenhauer; Timothy W Synold; Nancy Wainman; Lesley Seymour Journal: Invest New Drugs Date: 2007-10-26 Impact factor: 3.850
Authors: Roman Sakowicz; Jeffrey T Finer; Christophe Beraud; Anne Crompton; Evan Lewis; Alex Fritsch; Yan Lee; John Mak; Robert Moody; Rebecca Turincio; John C Chabala; Paul Gonzales; Stephanie Roth; Steve Weitman; Kenneth W Wood Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701
Authors: Jennifer J Knox; Sharlene Gill; Timothy W Synold; James J Biagi; Pierre Major; Ron Feld; Christine Cripps; Nancy Wainman; Elizabeth Eisenhauer; Lesley Seymour Journal: Invest New Drugs Date: 2008-01-15 Impact factor: 3.850
Authors: Richard Woessner; Brian Tunquist; Christine Lemieux; Elizabeth Chlipala; Steve Jackinsky; Walter Dewolf; Walter Voegtli; April Cox; Sumeet Rana; Patrice Lee; Duncan Walker Journal: Anticancer Res Date: 2009-11 Impact factor: 2.480
Authors: S Culine; C Theodore; M De Santis; B Bui; T Demkow; J Lorenz; F Rolland; F-M Delgado; B Longerey; N James Journal: Br J Cancer Date: 2006-05-22 Impact factor: 7.640
Authors: Shrikanta Chattopadhyay; Alison L Stewart; Siddhartha Mukherjee; Cherrie Huang; Kimberly A Hartwell; Peter G Miller; Radhika Subramanian; Leigh C Carmody; Rushdia Z Yusuf; David B Sykes; Joshiawa Paulk; Amedeo Vetere; Sonia Vallet; Loredana Santo; Diana D Cirstea; Teru Hideshima; Vlado Dančík; Max M Majireck; Mahmud M Hussain; Shambhavi Singh; Ryan Quiroz; Jonathan Iaconelli; Rakesh Karmacharya; Nicola J Tolliday; Paul A Clemons; Malcolm A S Moore; Andrew M Stern; Alykhan F Shamji; Benjamin L Ebert; Todd R Golub; Noopur S Raje; David T Scadden; Stuart L Schreiber Journal: Cell Rep Date: 2015-02-05 Impact factor: 9.423
Authors: Anna C Impastato; Andrej Shemet; Nynke A Vepřek; Gadiel Saper; Henry Hess; Lu Rao; Arne Gennerich; Dirk Trauner Journal: Angew Chem Int Ed Engl Date: 2022-01-14 Impact factor: 16.823
Authors: Leena J Laine; Jenni H E Mäki-Jouppila; Emma Kutvonen; Pekka Tiikkainen; Thomas K M Nyholm; Jerry F Tien; Neil T Umbreit; Ville Härmä; Lila Kallio; Trisha N Davis; Charles L Asbury; Antti Poso; Gary J Gorbsky; Marko J Kallio Journal: Oncoscience Date: 2021-12-10